Prevention effect of fenofibrate/pioglitazone in obese diabetic patients

Effect of fenofibrate alone and in combination on serum sirtuin 1 and fetuin A levels

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201407000856135

Enrollment

Registered

2014-07-16

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine T2DM, obesity

Interventions

fenofibrate

fenofibrate/pioglitazone

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Subjects suffering from type 2 DM for at least 5 years and body mass index (BMI) > 30 for diabetic patients groups, Over 50 years of age for females, No definite indication for receiving, and no contraindication to receiving fenofibrate (and pioglitazone for Group 2) in addition to their existing therapy.

Exclusion criteria

Exclusion criteria: Subjects with type 1 diabetes, Allergy to any fibrate drugs, Allergy or contraindication for pioglitazone drug (for Group 2), History of pancreatitis or pulmonary embolism or deep venous thrombosis, Use of any other investigational agents in last 8 weeks, Unstable condition including recent MI, heart failure, prior organ transplant, severe renal or liver dysfunction, history of myositis or untreated hypothyroidism, Pregnancy and lactation.

Design outcomes

Primary

Measure	Time frame
serum sirtuin 1 level	—

Secondary

Measure	Time frame
serum fetuin A level	—

Countries

Egypt

Contacts

Public ContactMohamed Noureldein

TA department of biochemistry

m.hussein@pharma.asu.edu.eg00201004684408

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026